Daewoong joins in competition in the Forxiga generic market

through a transfer and acquisition deal

Owns nearly 6 years of experience selling the original Forxiga from 2018

Will need to keep an eye out for changes in the generic market in line with Forxiga’s withdrawal

Daewoong Pharmaceutical, which had been in charge of the domestic sales and marketing of the original SGLT-2 diabetes drug ‘Forxiga (propanediol hydrate),’ is belatedly entering the generic market through a transfer and acquisition deal.

 

Daewoong had sold Forxiga until January this year.

 

It is analyzed that Daewoong also entered the generic market after AstraZeneca announced its plan to withdraw the drug from the Korean market in the second half of this year.

 

According to the industry on the 5th, Daewoong Pharmaceutical will be listing its Forxiga generic ‘Forxilo Tablet 5mg' at a ceiling price of KRW 262 from April through a transfer and acquisition.

 

Daewoong reportedly acquired Zalozin Tab 5mg from NBK Pharm.

 

The drug is produced by Dongkoo Bio&Pharma upon consignment.

 

Daewoong also acquired the license for Forxilo 10mg in January through an assignment and transfer deal Daewoong did not enter the generic market when Forxiga’s patent expired in April last year because it was selling the original Forxiga Tab at the time.

 

Daewoong has been in charge of domestic sales and marketing of AstraZeneca's Forxiga since March 2018.

 

The company continued to sell Forxiga even after launching its SGLT-2 class drug Envlo (enavogliflozin) in May last year.

 

However, its ties with AstraZeneca ended at the end of the past year with AstraZeneca’s announcement that it will discontinue sales of Forxiga in Korea.

 

In January, Daewoong stopped the distribution and sales of Forxiga, and HK Inno.N took over.

 

Daewoong's entry into the generic market is expected to change the competitive landscape of the market.

 

In particular, generic companies are expected to compete fiercely for the remaining pie once the original withdraws from the domestic market in the second half of the year.

 

Although Daewoong is focusing on promoting its own new drug Envlo, the pharmaceutical industry believes that the power and experience the company had accumulated selling the original Forxiga for 6 years is a force to be reckoned with.

 

Another factor that will affect the market structure is that from April 8, the generic pricing premium applied to innovative Forxiga generic drugs will end.

 

This is because the reduced drug price is likely to reduce promotion costs.

 

However, the pricing premium will be maintained on April 8, 2026, for salt-modified drugs produced by three or fewer generic companies.